Elan Corporation, plc ELN and Wyeth WYE today are presenting detailed results from the companies ’ 18-month Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer’s disease at the Alzheimer ’ s Association ’ s Read More

IRVINE, Calif., Feb. 20 /PRNewswire/ — LifeMasters Supported SelfCare, Inc., a national provider of health improvement services, announced that it has received an extension from the Centers for Medicare & Medicaid Services (CMS) of its disease Read More

This entry was posted on Thursday, July 31st, 2008 at 12:30 pm and is filed under primary pulmonary hypertension. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.